Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Cystoid macular edema associated with chemotherapy

Rajesh C. Rao and Netan Choudhry
CMAJ February 16, 2016 188 (3) 216; DOI: https://doi.org/10.1503/cmaj.131080
Rajesh C. Rao
W.K. Kellogg Eye Center (Rao), University of Michigan Medical School, Ann Arbor, Mich.; Herzig Eye Institute (Choudhry), Toronto, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Netan Choudhry
W.K. Kellogg Eye Center (Rao), University of Michigan Medical School, Ann Arbor, Mich.; Herzig Eye Institute (Choudhry), Toronto, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

A 45-year-old woman with recurrent breast cancer, who was otherwise healthy, presented to the ophthalmology clinic with a one-month history of decreased vision in both eyes. On examination, her visual acuity was 0.05 and her intraocular pressure was 14 mm Hg in both eyes. Slit-lamp examination showed asymmetric optic discs and cystoid macular edema (Figure 1A and B). Fluorescein angiography showed only trace leakage from the retinal capillaries (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.131080/-/DC1). The differential diagnosis for cystoid macular edema without substantial leakage includes nicotinic acid–associated maculopathy, X-linked juvenile retinoschisis, various forms of retinitis pigmentosa and taxane-associated maculopathy (e.g., paclitaxel and docetaxel).

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Funduscopic examination showing cystoid macular edema in the (A) right and (B) left eye (arrowheads) in a 45-year-old woman with recurrent breast cancer. (C) Spectral-domain optical coherence tomogram at the level of the right fovea showing intraretinal fluid in the outer plexiform layer (arrowhead) and cystoid changes in the inner retinal layer (arrow).

A review of the patient’s medications showed that she had received weekly treatment with nanoparticle albumin-bound paclitaxel (130 mg/m2) several months prior to this visit. She was not taking nicotinic acid, and there were no symptoms or a family history suggestive of retinitis pigmentosa. The findings in this case were consistent with taxane-associated maculopathy. After consultation with her oncologist, the patient discontinued treatment with nanoparticle albumin-bound paclitaxel, and, on follow-up examination, her vision had improved to 0.32 and 0.625 in the right and left eye, respectively. Consistent with this improvement, clinical examination confirmed a mild decrease in the cystoid macular edema, although imaging was not performed. Unfortunately, the patient died of complications associated with breast cancer after the follow-up visit.

Nanoparticle albumin-bound paclitaxel is a microtubule-stabilizing agent used to treat advanced breast, pancreatic, lung and ovarian cancers. This formulation and other taxanes, including paclitaxel and docetaxel, are linked to a serious toxic effect: reversible cystoid macular edema.1–4 Changes in vision have been reported in 13% of patients taking nanoparticle albumin-bound paclitaxel; visual disturbances were severe in only 1% of patients.1 Most toxic effects related to nanoparticle albumin-bound paclitaxel have involved the anterior segment (e.g., dry eye, keratitis) and doses greater than 300–375 mg/m2.1 Previous approaches used to treat taxane-associated maculopathy have included discontinuation of the drug, topical carbonic anhydrase agents and intravitreal injection of antivascular endothelial factor antibodies.2–5 The efficacy of the pharmacologic approaches remains unknown because of the small number of patients. Clinicians caring for patients undergoing taxane-based chemotherapy should remain alert to changes in vision and consider prompt referral to an ophthalmologist, because cessation of treatment can be associated with improvement in vision.

Footnotes

  • Competing interests: Rajesh Rao has received a grant from the US National Institutes of Health (K12EY022299). No competing interests were declared by Netan Choudhry.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

References

  1. ↵
    1. Gradishar WJ,
    2. Tjulandin S,
    3. Davidson N,
    4. et al
    . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–803.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Smith SV,
    2. Benz MS,
    3. Brown DM
    . Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008; 126:1605–6.
    OpenUrlCrossRefPubMed
    1. Rahimy E,
    2. Sarraf D
    . Cystoid macular edema secondary to nanoparticle albumin-bound Paclitaxel therapy. Ophthalmic Surg Lasers Imaging Retina 2013;44:187–9.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rahman HT,
    2. Yeh S,
    3. Bergstrom CS
    . Cystoid macular edema without leakage secondary to nab-paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther 2013; 29:360–2.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ehlers JP,
    2. Rayess H,
    3. Steinle N
    . Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond) 2013;27:102–4.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (3)
CMAJ
Vol. 188, Issue 3
16 Feb 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cystoid macular edema associated with chemotherapy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cystoid macular edema associated with chemotherapy
Rajesh C. Rao, Netan Choudhry
CMAJ Feb 2016, 188 (3) 216; DOI: 10.1503/cmaj.131080

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Cystoid macular edema associated with chemotherapy
Rajesh C. Rao, Netan Choudhry
CMAJ Feb 2016, 188 (3) 216; DOI: 10.1503/cmaj.131080
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Topical nonsteroidal anti-inflammatory drugs
  • Postcoital bleeding
  • Phlegmonous gastritis
Show more Practice

Similar Articles

Collections

  • Topics
    • Cancer & oncology
    • Family medicine, general practice, primary care
    • Ophthalmology
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire